Jaguar Health Sells $500K in Stock Privately
Ticker: JAGX · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1585608
Sentiment: neutral
Topics: equity-sale, private-placement, capital-raise
TL;DR
Jaguar Health just sold $500K in stock privately at $0.50/share.
AI Summary
On March 5, 2024, Jaguar Health, Inc. filed an 8-K report detailing an unregistered sale of equity securities. The company issued 1,000,000 shares of its common stock at a purchase price of $0.50 per share, totaling $500,000. This transaction was part of a private placement.
Why It Matters
This filing indicates Jaguar Health has raised capital through a private placement, which could impact its financial flexibility and future operations.
Risk Assessment
Risk Level: medium — Unregistered sales of equity securities can sometimes signal a need for capital or potential dilution for existing shareholders.
Key Numbers
- $500,000 — Proceeds from Equity Sale (Capital raised through private placement)
- 1,000,000 — Shares Sold (Number of common stock shares issued)
- $0.50 — Price Per Share (Purchase price in the private placement)
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- 1,000,000 (dollar_amount) — Number of shares sold
- $0.50 (dollar_amount) — Price per share
- $500,000 (dollar_amount) — Total proceeds from sale
FAQ
What type of securities were sold in the unregistered offering?
The filing states that 1,000,000 shares of the company's common stock were sold.
What was the total amount of capital raised in this transaction?
The company raised a total of $500,000 from the sale of 1,000,000 shares at $0.50 per share.
When did the event reported in this 8-K occur?
The earliest event reported in this 8-K occurred on March 5, 2024.
Was this offering registered with the SEC?
No, the filing explicitly states it is an 'Unregistered Sales of Equity Securities'.
What is the price per share for the common stock sold?
The common stock was sold at a purchase price of $0.50 per share.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-08 17:00:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
Filing Documents
- tm248372d1_8k.htm (8-K) — 26KB
- 0001104659-24-032468.txt ( ) — 195KB
- jagx-20240305.xsd (EX-101.SCH) — 3KB
- jagx-20240305_lab.xml (EX-101.LAB) — 33KB
- jagx-20240305_pre.xml (EX-101.PRE) — 22KB
- tm248372d1_8k_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on March 1, 2024, Jaguar Health, Inc. (the "Company") issued an aggregate of 179.3822 shares of Series J Preferred Stock to Streeterville Capital, LLC ("Streeterville") pursuant to a privately negotiated exchange agreement. On March 5, 2024, the Company entered into a privately negotiated exchange agreement with Streeterville (the "Exchange Agreement"), pursuant to which the Company issued 10,000,000 shares of the Company's common stock in exchange for the surrender and cancellation of 40 shares of Series J Perpetual Preferred Stock. The shares of common stock that were issued in the exchange transaction described above were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended. The form of Exchange Agreement was filed as Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019, which is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Form of Exchange Agreement (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019). 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: March 8, 2024